Cobenfy to be priced at the same level as in the United States.
Bristol Myers Squibb announced plans to launch its schizophrenia drug Cobenfy in the United Kingdom at the same price as in the United States, drawing attention to ongoing debates over pharmaceutical pricing in global markets.